title: A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer.
abstract: OBJECTIVE
  Docetaxel is an active agent as first-line chemotherapy in patients with advanced breast cancer at a dosage of 100 mg/m2. However, the efficacy of this agent as a first-line drug when used at a lower dosage is unclear. This study was performed to evaluate the clinical efficacy and safety of 60 mg/m2 docetaxel for the treatment of breast cancer.
  
  
  METHODS
  This study enrolled 23 patients with advanced and/or metastatic breast cancer, who had not been treated with an anthracycline or taxane previously. Treatment with docetaxel was continued in patients showing a response until there was evidence of disease progression or unacceptable toxicity.
  
  
  RESULTS
  Among 20 fully evaluated patients, the overall response rate was 50.0% and the median time to progression was 31 weeks. The most commonly observed adverse events were neutropenia (78.2%) and fatigue (60.9%). Fluid retention occurred in only 8.7% of the patients. Adverse events did not cause discontinuation of the treatment.
  
  
  CONCLUSIONS
  Docetaxel achieved good disease control with mild adverse events in first-line treatment at a dosage of 60 mg/m2.
authors.affiliation: Department of General Surgery, Yokohama City University Medical Center, Minami-ku, Yokohama 232-0024, Japan. tishik@urahp.yokohama-cu.ac.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Satoru
authors.initials: S
authors.lastname: Shimizu
authors.forename: Masaaki
authors.initials: M
authors.lastname: Inaba
authors.forename: Taro
authors.initials: T
authors.lastname: Asaga
authors.forename: Kiyohumi
authors.initials: K
authors.lastname: Katayama
authors.forename: Mamoru
authors.initials: M
authors.lastname: Fukuda
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tokuda
authors.forename: Kazuo
authors.initials: K
authors.lastname: Ishida
authors.forename: Eisuke
authors.initials: E
authors.lastname: Fukuma
authors.forename: Takashi
authors.initials: T
authors.lastname: Suda
authors.forename: Yohei
authors.initials: Y
authors.lastname: Hamaguchi
authors.forename: Akira
authors.initials: A
authors.lastname: Ishiyama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shimada
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007564:Japan; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010166:Palliative Care; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel